GTx, Inc. Share Price Nasdaq
Equities
US40052B2079
Biotechnology & Medical Research
Sales 2024 * | 569K 44.84M | Sales 2025 * | 675K 53.19M | Capitalization | 26.16M 2.06B |
---|---|---|---|---|---|
Net income 2024 * | -35M -2.76B | Net income 2025 * | -48M -3.78B | EV / Sales 2024 * | 46 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 38.8 x |
P/E ratio 2024 * |
-0.74
x | P/E ratio 2025 * |
-1.05
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.77% |
Latest transcript on GTx, Inc.
Managers | Title | Age | Since |
---|---|---|---|
James Breitmeyer
FOU | Founder | 70 | 31/12/96 |
Richard Vincent
DFI | Director of Finance/CFO | 61 | 31/03/17 |
Salim Yazji
CTO | Chief Tech/Sci/R&D Officer | 55 | 16/05/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Hale
FOU | Founder | 75 | 31/12/96 |
Dan Kisner
BRD | Director/Board Member | 77 | 06/06/19 |
Rosemary Mazanet
BRD | Director/Board Member | 67 | 26/01/21 |
1st Jan change | Capi. | |
---|---|---|
+29.77% | 49.18B | |
+1.00% | 42.11B | |
+50.47% | 40.37B | |
-5.26% | 28.85B | |
+13.68% | 26.09B | |
-22.99% | 18.71B | |
+8.22% | 13.26B | |
+32.41% | 12.32B | |
-1.62% | 11.99B |